Skip to content

Comparison of the efficacy and safety using 0.01% vs 0.03% bimatoprost for the treatment of eyebrow hypotrichosis: A randomized, double-blind study

Comparison of the efficacy and safety using 0.01% vs 0.03% bimatoprost for the treatment of eyebrow hypotrichosis: A randomized, double-blind study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20171130004
Enrollment
Unknown
Registered
2017-11-30
Start date
2018-01-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eyebrow hypotrichosis eyebrow hypotrichosis

Interventions

0.01% Bimatoprost was proved to be effective in the treatment of eyebrows hypotrichosis in our latest study,0.03% Bimatoprost was proved to be effective in the treatment of eyebrows hypotrichosis in p
Experimental Drug,Active Comparator Drug
0.01% Bimatoprost,0.03% Bimatoprost

Sponsors

Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol U
Lead Sponsor
Mahidol University
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with eyebrow hypotrichosis 2.Age more than 18 year-old 3.No serious underlying diseases 4.Informed consent 5.Compatible with follow-up schedule

Exclusion criteria

Exclusion criteria: 1.Patients undergone eyebrow transplantation 2.Previously treated with drugs or products affecting eyebrow cycle within 2 wks 3.Previously treated with minoxidil, systemic antiandrogen, topical estrogen/progesterone, topical prostaglandin analogs, anabolic steroids, lithium, phenothiazines 4.Patients with underlying diseases involving eyebrow hypotrichosis eg. Cancer, immunocompromised, thyroid diseases or psychiatric disorders including trichotillomania 5.Patients undergone eyebrow tattooing 6.Patients with history of poor wound healing or with skin pathology on eyebrow 7.Allergic to bimatoprost 8.Pregnancy or lactation 9.Withdraw

Design outcomes

Primary

MeasureTime frame
The Global Eyebrow Assessment (GEBA) scale Week 0, Week 24 Photos taken with VISIA and evaluated by blinded dermatologists,Eyebrow hypotrichosis improvement Week 24 7-point rating scale by photos taken with VISIA and evaluated by blinded dermatologists and patients,Eyebrows density and diameter Week 0, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 Folliscope® (LeadM Corporation, Seoul, South Korea)

Secondary

MeasureTime frame
Adverse effects (eg. itchiness, erythema etc.) Week 0, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 Evaluated from patients and attending dermatologists,Patient satisfaction Week 24 Patients satisfaction rating score

Countries

Thailand

Contacts

Public ContactSarawin Harnchoowong

Division of Dermatology, Faculty of Medicine Ramathibodi Hospital

hsarawin@gmail.com6622011211

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026